Sign in

    Miriam Funt • JPMorgan Chase & Co.

    Miriam Funt is an Executive Director and Equity Research Analyst at JPMorgan Chase & Co., specializing in US Restaurants coverage with detailed analysis and recommendations for major companies including McDonald’s, Starbucks, Yum! Brands, Domino’s Pizza, and Chipotle Mexican Grill. Recognized for her thorough sector insights, she has contributed to high-quality research products that inform institutional investors and has earned credibility for consistently accurate and actionable stock calls, though specific performance metrics like TipRanks success rates or returns are not publicly available. Funt began her career as an analyst at J.P. Morgan in 2014 and steadily advanced within the firm to her current leadership position, building her expertise through roles exclusively at JPMorgan. She holds Series 7, 63, 86, and 87 FINRA securities licenses, further solidifying her professional credentials as an equity research analyst.

    Miriam Funt's questions to Immunovant Inc (IMVT) leadership

    Miriam Funt's questions to Immunovant Inc (IMVT) leadership • Q3 2024

    Question

    Miriam Funt of JPMorgan Chase & Co. asked how the recently presented extrathyroidal benefits in Graves' disease read through to the ongoing Thyroid Eye Disease (TED) trial and questioned the updated timeline for the TED data readout. She also inquired about the potential for FcRn inhibitors to move into earlier lines of RA treatment.

    Answer

    Executive Peter Salzmann explained that seeing proptosis changes in a Graves' population with mostly mild TED is encouraging for the broader strategy of treating TED earlier. He confirmed the TED data is now expected in the second half of next year due to competition for patients in the narrow trial slice. Dr. Peter Taylor addressed the RA question, stating that while theoretically possible, the prevalence of cheaper biosimilars and generics makes it likely that new therapies will focus on the high unmet need in the difficult-to-treat population.

    Ask Fintool Equity Research AI